First-pass extracted concept

6-dimethylaminopurine

Candidate: toolkit item1 source documents6 linked claims
Live refresh every 5sNext refresh in 5s

Aliases

6-DMAP

Evidence Snippets

The effects of 6-dimethylaminopurine (6-DMAP), known to reversibly block cell division in many systems through inhibition of protein kinase activity, are described here for Gonyaulax.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1biological effectsupports1994Source 1DOIPubMed

In Gonyaulax polyedra, continuous exposure to 6-DMAP lengthens the circadian period in a concentration-dependent fashion.

Quoted textsource-backed
in cells continuously exposed, the period is lengthened in a concentration-dependent fashion
Claim 2biological effectsupports1994Source 1DOIPubMed

Short treatments with 5 mM 6-DMAP apparently stop the circadian oscillator reversibly in Gonyaulax polyedra.

Quoted textsource-backed
Shorter treatments at a higher concentration of 6-DMAP (5 mM) apparently stop the circadian oscillator, but reversibly so
Claim 3in vitro activitysupports1994Source 1DOIPubMed

6-DMAP is effective in inhibiting many Gonyaulax protein kinases in vitro.

Quoted textsource-backed
6-DMAP completely blocks light-induced phase advances and is effective in inhibiting many Gonyaulax protein kinases in vitro.
Claim 4light response inhibitionsupports1994Source 1DOIPubMed

6-DMAP completely blocks light-induced phase advances in Gonyaulax polyedra.

Quoted textsource-backed
6-DMAP completely blocks light-induced phase advances
Claim 5phase shifting effectsupports1994Source 1DOIPubMed

Pulses of 6-DMAP cause phase delays at all times of the circadian cycle in Gonyaulax polyedra.

Quoted textsource-backed
Pulses of the inhibitor are effective in causing phase delays at all times of the circadian cycle.
Claim 6reversibilitysupports1994Source 1DOIPubMed

After removal of 6-DMAP, the circadian rhythm resumes with a phase delay approximately equal to the duration of treatment.

Quoted textsource-backed
the rhythm resumes after drug removal with a phase delay approximately equal to the duration of the treatment